Is Avadel Pharmaceuticals plc (AVDL) a Buy, Sell, or Hold?
NASDAQ : AVDL
Avadel Pharmaceuticals plc — News
$21.64 USD
$0 (0.0%)
- Volume
- 35.02M
- Average Volume
- 2.42M
- Market Capitalization
- $2.12B
- P/E Ratio
- 431.08
- Dividend Yield
- 0.00%
- Price Target
- $20.00
- Year High
- $23.57
- Year Low
- $6.38
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.76
| Source | Headline |
|---|---|
|
Alkermes: 'Buy' On Avadel Acquisition And Positive NT2 Data With Alixorexton
Alkermes plc maintains a Buy rating, driven by the accretive Avadel Pharmaceuticals acquisition and strong pipeline progress. Company bolstered its hypersomnolence portfolio with LUMRYZ, which delivered robust early sales and revenue momentum post-acquisition. Positive phase 2 data for alixorexton in narcolepsy type 2 and ongoing phase 3 Brilliance Studies underpin a compelling growth thesis. seekingalpha.com - 2026-06-19 15:49:55 |
